Literature DB >> 12373570

Glycogen storage disease type I: pathophysiology of liver adenomas.

Philip J Lee1.   

Abstract

UNLABELLED: Of the many complications associated with glycogen storage disease type I, hepatic tumours cause great concern because of their malignant potential and the current difficulties in monitoring them. Hepatic adenomas occur in 22%-75% of affected adults, according to the population studied, and from those reported in the literature are thought to have an approximately 10% risk of undergoing malignant transformation. Their aetiology is unclear, but they occur generally in post-pubertal patients, and can be either single or multiple. This article discusses theories of their aetiology, methods of detection and monitoring, and treatment options.
CONCLUSION: the incidence of liver tumours in younger adults seems less than in older ones, suggesting that better dietary treatment, and thus improved metabolic control, may be protective. Surgery (partial hepatectomy or orthotopic liver transplantation) is the definitive therapy for these tumours, but the timing of this intervention is difficult to determine and it is not without its own hazards.

Entities:  

Mesh:

Year:  2002        PMID: 12373570     DOI: 10.1007/s00431-002-1002-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  28 in total

1.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

3.  Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.

Authors:  Wai Han Yiu; Chi-Jiunn Pan; Paul A Mead; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  J Hepatol       Date:  2009-02-05       Impact factor: 25.083

Review 4.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

Review 5.  Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Hum Mutat       Date:  2008-07       Impact factor: 4.878

6.  Multiple hepatic adenomas in a child with microvillus inclusion disease.

Authors:  Jennifer C Burgis; C Allan Pratt; John P T Higgins; John A Kerner
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

7.  Perioperative management of hemostasis for surgery of benign hepatic adenomas in patients with glycogen storage disease type ia.

Authors:  Alix Mollet-Boudjemline; Aurélie Hubert-Buron; Catherine Boyer-Neumann; Roxana Aldea; Dominique Franco; Pascale Trioche-Eberschweiller; Anne-Elisabeth Mas; Mylène Mabille; Philippe Labrune; Vincent Gajdos
Journal:  JIMD Rep       Date:  2011-06-22

8.  Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

Authors:  David Q Wang; Laurie M Fiske; Caroline T Carreras; David A Weinstein
Journal:  J Pediatr       Date:  2011-04-09       Impact factor: 4.406

9.  Malignant transformation of hepatocellular adenoma with bone marrow metaplasia arising in glycogen storage disease type I: A case report.

Authors:  Tomohiro Iguchi; Motoyuki Yamagata; Takashi Sonoda; Kimihiko Yanagita; Tetsuhiro Fukahori; Eiji Tsujita; Shinichi Aishima; Yoshinao Oda; Yoshihiko Maehara
Journal:  Mol Clin Oncol       Date:  2016-09-21

Review 10.  [Surgical therapy of benign liver tumors].

Authors:  M Loss; C Zülke; A Obed; O Stöltzing; H J Schlitt
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.